Higher PD-L1 expression in FA-AML1 may also account for prolonged overall survival in FA-AML1 engrafted mice, as patients with higher PD-L1 expression have higher response rates to anti-PD-1/PD-L1 therapy [37, 38]. The gene discussed is RUNX1; the disease is Friedreich ataxia.